The CDA Foundation. Polaris Dashboard. 2024 [cited 2024 8 November]. https://cdafound.org/polaris/dashboard/

Ghany MG, Buti M, Lampertico P, et al. Guidance on treatment endpoints and study design for clinical trials aiming to achieve cure in chronic hepatitis B and D: report from the 2022 AASLD-EASL HBV-HDV Treatment Endpoints Conference. Hepatology. 2023;78(5):1654–73.

Article  PubMed  Google Scholar 

Mak LY, Seto WK, Hui RW, et al. Fibrosis evolution in chronic hepatitis B e antigen-negative patients across a 10-year interval. J Viral Hepatitis. 2019;26(7):818–27.

Article  CAS  Google Scholar 

Hui RW, Mak LY, Cheung TT, et al. Clinical practice guidelines and real-life practice on hepatocellular carcinoma: the Hong Kong perspective. Clin Mol Hepatol. 2022;29(2):217–29 (ePub ahead of print).

Article  PubMed  PubMed Central  Google Scholar 

Mak LY, Hui RW, Chung MSH, et al. Regression of liver fibrosis after HBsAg loss: a prospective matched case-control evaluation using transient elastography and serum enhanced liver fibrosis test. J Gastroenterol Hepatol. 2024. https://doi.org/10.1111/jgh.16728.

Article  PubMed  Google Scholar 

Mak LY, Hui RW, Fung J, et al. The role of different viral biomarkers on the management of chronic hepatitis B. Clin Mol Hepatol. 2023;29(2):263–76.

Article  PubMed  PubMed Central  Google Scholar 

Seto WK, Lo YR, Pawlotsky JM, et al. Chronic hepatitis B virus infection. Lancet. 2018;392(10161):2313–24.

Article  PubMed  Google Scholar 

Hui RW, Mak LY, Seto WK, et al. Assessing the developing pharmacotherapeutic landscape in hepatitis B treatment: a spotlight on drugs in phase II clinical trials. Expert Opin Emerg Drugs. 2022;27(2):127–40.

Article  CAS  PubMed  Google Scholar 

Wedemeyer H, Aleman S, Brunetto MR, et al. A phase 3, randomized trial of bulevirtide in chronic hepatitis D. N Engl J Med. 2023;389(1):22–32.

Article  CAS  PubMed  Google Scholar 

Erken R, Andre P, Roy E, et al. Farnesoid X receptor agonist for the treatment of chronic hepatitis B: a safety study. J Viral Hepat. 2021;28(12):1690–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hui RW, Mak LY, Seto WK, et al. RNA interference as a novel treatment strategy for chronic hepatitis B infection. Clin Mol Hepatol. 2022;28:408–24.

Article  PubMed  PubMed Central  Google Scholar 

Hui RW, Mak LY, Seto WK, et al. Role of core/capsid inhibitors in functional cure strategies for chronic hepatitis B. Curr Hepat Rep. 2020;19(3):293–301.

Article  Google Scholar 

Bazinet M, Pântea V, Placinta G, et al. Safety and efficacy of 48 weeks REP 2139 or REP 2165, tenofovir disoproxil, and pegylated interferon Alfa-2a in patients with chronic HBV infection naïve to nucleos(t)ide therapy. Gastroenterology. 2020;158(8):2180–94.

Article  CAS  PubMed  Google Scholar 

Gane EJ, Dunbar PR, Brooks AE, et al. Safety and efficacy of the oral TLR8 agonist selgantolimod in individuals with chronic hepatitis B under viral suppression. J Hepatol. 2023;78(3):513–23.

Article  CAS  PubMed  Google Scholar 

Wang G, Cui Y, Hu G, et al. HBsAg loss in chronic hepatitis B patients after 24-week treatment with subcutaneously administered PD-L1 antibody ASC22 (Envafolimab): interim results from a phase IIb extension cohort. In: The Liver Meeting, 2023; Boston, US2023.

Ma H, Lim TH, Leerapun A, et al. Therapeutic vaccine BRII-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study. JHEP Rep. 2021;3(6): 100361.

Article  PubMed  PubMed Central  Google Scholar 

Agarwal K, Yuen M-F, Wedemeyer H, et al. Reduction in hepatitis B viral DNA and hepatitis B surface antigen following administration of a single dose of VIR-3434, an investigational neutralizing monoclonal antibody: first experience in a population with viremia. Hepatology. 2022;76:S303–4.

Google Scholar 

Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391(6669):806–11.

Article  CAS  PubMed  Google Scholar 

Elbashir SM, Harborth J, Lendeckel W, et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001;411(6836):494–8.

Article  CAS  PubMed  Google Scholar 

Pratt AJ, MacRae IJ. The RNA-induced silencing complex: a versatile gene-silencing machine. J Biol Chem. 2009;284(27):17897–901.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Caplen NJ, Parrish S, Imani F, et al. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc Natl Acad Sci USA. 2001;98(17):9742–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yuan YR, Pei Y, Ma JB, et al. Crystal structure of A. aeolicus argonaute, a site-specific DNA-guided endoribonuclease, provides insights into RISC-mediated mRNA cleavage. Mol Cell. 2005;19(3):405–19.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rivas FV, Tolia NH, Song JJ, et al. Purified Argonaute2 and an siRNA form recombinant human RISC. Nat Struct Mol Biol. 2005;12(4):340–9.

Article  CAS  PubMed  Google Scholar 

Petersen CP, Bordeleau ME, Pelletier J, et al. Short RNAs repress translation after initiation in mammalian cells. Mol Cell. 2006;21(4):533–42.

Article  CAS  PubMed  Google Scholar 

Watts JK, Corey DR. Silencing disease genes in the laboratory and the clinic. J Pathol. 2012;226(2):365–79.

Article  CAS  PubMed  Google Scholar 

Springer AD, Dowdy SF. GalNAc-siRNA conjugates: leading the way for delivery of RNAi therapeutics. Nucleic Acid Ther. 2018;28(3):109–18.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dominska M, Dykxhoorn DM. Breaking down the barriers: siRNA delivery and endosome escape. J Cell Sci. 2010;123(Pt 8):1183–9.

Article  CAS  PubMed  Google Scholar 

Linnane E, Davey P, Zhang P, et al. Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines. Nucleic Acids Res. 2019;47(9):4375–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Liang XH, Sun H, Nichols JG, et al. RNase H1-dependent antisense oligonucleotides are robustly active in directing RNA cleavage in both the cytoplasm and the nucleus. Mol Ther. 2017;25(9):2075–92.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18(6):421–46.

Article  CAS  PubMed  Google Scholar 

Gavrilov K, Saltzman WM. Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med. 2012;85(2):187–200.

CAS  PubMed  PubMed Central  Google Scholar 

Roh EH, Sullivan MO, Epps TH 3rd. A kinetic modeling platform for predicting the efficacy of siRNA formulations in vitro and in vivo. STAR Protoc. 2022;3(4): 101723.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21.

Article  CAS  PubMed